Published in Biotech Business Week, June 15th, 2006
The company will launch the product immediately under the trade name Claravis. The company will now market the full line of Isotretinoin product strengths, including Claravis 10 mg, 20 mg, 30 mg and 40 mg capsules.
Claravis Capsules, 30 mg will compete with Ranbaxy's Sotret (Isotretinoin) Capsules USP, 30 mg that had total annual sales of approximately $15 million for the most recent 12 months ending March 2006, based...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.